National Pharmaceutical Council (NPC) President Robert Dubois in a recent article published on the American Journal of Managed Care (AJMC) suggests having only one group performing drug assessments is insufficient.
Having only one group perform these reviews, such as the Institute for Clinical and Economic Review (ICER) and the U.K.’s National Institute for Health and Care Excellence (NICE), and producing only a single incremental cost-effectiveness ratio present obstacles for reflecting the diversity of patients.
“Given this myriad of differences, a single incremental cost-effectiveness ratio, or even a few subgroup analyses, cannot adequately reflect what is important to a diverse group of patients,” Dubois writes. “To reflect those important differences, a range of values or multiple incremental cost-effectiveness ratios are needed.”
To read the full article on AJMC, click here.